PAA
Director Trades
| Date | Director | Value |
|---|
Company News
PharmAust seeks European orphan drug designation for MND/ALS drug monepantel
PharmAust (ASX: PAA) has requested the European Medicines Agency (EMA) grant orphan medicinal product designation (OMPD) for monepantel (MPL), its lead candidate in the treatment of amyotrophic lateral sclerosis (ALS) and motor neurone disease (MND). The OMPD is an EMA initiative to encourage companies to develop safe and effective treatments for rare diseases or neglected […]
PharmAust reports encouraging interim results for ALS/MND drug monepantel in ongoing study
PharmAust (ASX: PAA) has received promising interim results from a major study into monepantel (MPL), its lead amyotrophic lateral sclerosis (ALS) / motor neurone disease (MND) treatment candidate. The clinical-stage biotechnology company revealed that treatment with MPL at 10 milligrams per kilogram of body weight daily continues to be well-tolerated, slowing disease progression and improving […]
PharmAust’s transformative quarter sees monepantel treatment gain ground on MND/ALS
The three months to end June marked a transformative quarter in PharmAust’s (ASX: PAA) focus on monepantel (MPL) for the treatment of neurodegenerative diseases. The company achieved numerous milestones in the development of MPL for motor neurone disease (MND) / amyotrophic lateral sclerosis (ALS). These included the granting of final ethics committee approval for an […]
PharmAust raises $7.8m in oversubscribed SPP to advance monepantel for MND/ALS treatment
PharmAust (ASX: PAA) has raised $7.8 million in a share purchase plan (SPP) to accelerate development of its lead candidate monepantel as a viable treatment for motor neurone disease (MND) / amyotrophic lateral sclerosis (ALS). Shareholder demand for the raising was greater than expected and exceeded the initial target of $2m, with the additional $5.8m […]
PharmAust’s monepantel selected for prestigious HEALEY ALS platform trial in the US
PharmAust’s (ASX: PAA) lead amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND) treatment candidate monepantel (MPL) has been selected for inclusion in the prestigious HEALEY ALS Phase 2/3 platform trial. The HEALEY trial is being conducted in the United States under a clinical research support agreement with Massachusetts General Hospital that allows multiple investigational treatments to […]
PharmAust awarded SME status in Europe, further promoting MND treatment
Clinical-stage biotechnology company PharmAust (ASX: PAA) has been granted small and medium-sized enterprise (SME) status by the European Medicines Agency (EMA). PharmAust is now eligible to receive regulatory fee incentives and additional support from the EMA, streamlining its regulatory engagement and the company’s ability to advance its monepantel (MPL) treatment for motor neurone disease (MND)/amyotrophic […]
PharmAust raises $10m to progress MPL neurodegenerative disease treatment
Clinical-stage biotechnology company PharmAust (ASX: PAA) has received strong market support for plans to progress its monepantel (MPL) neurodegenerative disease candidate. The company has received binding commitments to raise $10 million via an institutional placement at $0.19 per share. The placement was again strongly supported by the company’s directors and management, who participated for approximately […]
PharmAust’s breakthrough MND/ALS study showcased at major European medical conference
The success of PharmAust’s (ASX: PAA) Phase 1 MEND study into the treatment of motor neurone disease/amyotrophic lateral sclerosis (MND/ALS) is being showcased at a major global gathering of medical professionals in Stockholm, Sweden. Texas-based clinical trial design specialists Berry Consultants are presenting data from the Phase 1 MEND study at the annual meeting of […]
PharmAust appoints experienced US-based pharma executive to board of directors
Clinical-stage biotechnology company PharmAust (ASX: PAA) has appointed US-based Dr Katie MacFarlane as a non-executive director to the board. Dr MacFarlane has over 30 years’ experience in the development and commercialisation of pharmaceutical products and devices. The company sees her appointment as a further step toward it becoming a global leader in the treatment of […]
PharmAust encouraged by positive monepantel survival rate assessment
Clinical-stage biotechnology company PharmAust (ASX: PAA) has received positive survival benefit assessments for its monepantel (MPL) neurodegenerative disease treatment. A new study undertaken by specialists Berry Consultants indicates that MPL provides a statistically significant survival benefit for patients with motor neurone disease (MND) / amyotrophic lateral sclerosis (ALS) compared to untreated matched controls from the […]
Company Videos
PharmAust makes strong progress in monepantel study to treat MND/ALS
PharmAust’s new CEO on his journey in biotech and vision for the company
PharmAust ready to trial monepantel on humans to fight motor neurone disease
PharmAust progresses flagship Monepantel drug in treating canine lymphoma and COVID-19
Tony Locantro: what’s happening in the gold sector and 6 biotech stocks
